Plus Therapeutics (PSTV) Capital Expenditures (2010 - 2026)
Plus Therapeutics (PSTV) reported Capital Expenditures of $818000.0 for Q1 2026, up 27166.67% year-over-year from N/an in Q1 2025, and up 2626.67% quarter-over-quarter from $30000.0 in Q4 2025.
Plus Therapeutics (PSTV) Capital Expenditures (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 17 years of Capital Expenditures data on file, last reported at $818000.0 in Q1 2026.
- Capital Expenditures for Q1 2026 came in at $818000.0, up 27166.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $882000.0 (up 709.17% YoY), and the FY2025 annual result was $67000.0, down 54.11% from the prior year.
- Capital Expenditures grew to $818000.0 in Q1 2026 per PSTV's latest filing, from $30000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $818000.0 in Q1 2026 and troughed at $3000.0 in Q1 2025.
- A 5-year average of $100000.0 and a median of $33000.0 in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2025 and 2026: Capital Expenditures slumped 92.5% in 2025, then surged 27166.67% in 2026.
- A 5-year view of Capital Expenditures shows it stood at $128000.0 in 2022, then plunged by 67.19% to $42000.0 in 2023, then plunged by 73.81% to $11000.0 in 2024, then jumped by 172.73% to $30000.0 in 2025, then surged by 2626.67% to $818000.0 in 2026.
- Business Quant data shows PSTV's Capital Expenditures at $818000.0 in Q1 2026, $30000.0 in Q4 2025, and $27000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -63,220.27 |
| 10 | Plus Therapeutics | 34.26 Mn | 19.15 Mn | - | 818,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 818,000.00 |
| Mar 31, 2026 | 818,000.00 |
| Dec 31, 2025 | 30,000.00 |
| Dec 31, 2025 | 30,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Sep 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | 11,000.00 |
| Dec 31, 2024 | 11,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Jun 30, 2024 | 81,000.00 |
| Jun 30, 2024 | 81,000.00 |
| Mar 31, 2024 | 40,000.00 |
| Mar 31, 2024 | 40,000.00 |
| Dec 31, 2023 | 42,000.00 |
| Dec 31, 2023 | 42,000.00 |